Mavacamten Safety and Efficacy in a Heart Transplant Patient Exhibiting Obstructive Hypertrophic Cardiomyopathy Phenotype.
heart transplant
hypertrophic cardiomyopathy
left ventricular outflow tract obstruction
mavacamten
Journal
JACC. Case reports
ISSN: 2666-0849
Titre abrégé: JACC Case Rep
Pays: Netherlands
ID NLM: 101757292
Informations de publication
Date de publication:
21 Aug 2024
21 Aug 2024
Historique:
received:
25
04
2024
accepted:
21
05
2024
medline:
19
9
2024
pubmed:
19
9
2024
entrez:
19
9
2024
Statut:
epublish
Résumé
Hypertrophic cardiomyopathy is the most common inherited cardiac disease, exhibiting diverse phenotypes. Obstructive hypertrophic cardiomyopathy occurs in about two-thirds of cases and carries a worse prognosis. Mavacamten use in heart transplant recipients is limited. This paper reports a recipient who developed severe symptomatic obstructive hypertrophic cardiomyopathy phenotype/phenocopy and was initiated on mavacamten.
Identifiants
pubmed: 39295799
doi: 10.1016/j.jaccas.2024.102454
pii: S2666-0849(24)00247-X
pmc: PMC11405954
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Pagination
102454Informations de copyright
© 2024 The Authors.
Déclaration de conflit d'intérêts
Dr Abood’s time was supported by the Colton Scholarship, which played no role in this case or this manuscript, including the decision to submit it for publication. The authors have reported that they have no relationships relevant to the contents of this paper to disclose.